Some in vitro studies showed that chemical chaperones and a newly FDA-approved drug, Setmelanotide (an MC4R agonist), could be used to treat some monogenic forms of obesity due to POMC, PCSK1, or LEPR deficiency. This evidence concerns the gene PCSK1 and obesity due to melanocortin 4 receptor deficiency.